DENVER, April 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational…


Previous articleTryp Therapeutics Announces Listing on OTCQB and DTC Eligibility
Next articleWorking with Internal Family Systems (IFS) Therapy and Psychedelics: Everything You Need to Know